Noninvasive in vivo monitoring of gene delivery would provide a critically important information regarding the spatial distribution, local concentration, kinetics of removal and/or biodegradation of the expression vector. We developed a novel approach to noninvasive gene delivery imaging using heterobifunctional peptide-based chelates (PBC) bearing double-stranded DNA-binding groups and a technetiumbinding amino acid motif. One of such chelates: GlyCys(Acm)-Gly-Cys(Acm)-Gly-Lys 4 -Lys-(N-⑀-[4-(psoralen-8-yloxy)]butyrate)-NH 2 has been characterized and labeled with reduced 99m Tc pertechnetate (oxotechnetate). The psoralen moiety (a DNA binding group of PBC) allowed linking to double-stranded DNA upon short-term irradiation with the near UV range light (Ͼ320 nm). Approximately 30-40% of added 99m Tc-labeled PBC was nonextractable and coeluted with a model pCMV-GFP vector during the gel-permeation chromatography. Nuclear imaging of 'naked' DNA
Introduction
Despite recent advances in the field of vector and transgene development it has become apparent that insufficient delivery of genetic material to target cells in vivo, as well as low and/or transient gene expression hamper the effectiveness of gene therapy. As a result, a number of novel approaches are being pursued to target gene therapy vectors and to improve gene delivery. In order to compare and optimize different delivery strategies, it is important to assess vector delivery and gene expression quantitatively in intact animals and, eventually, in human patients. Imaging of gene delivery can be helpful in this endeavor as it allows: (1) longitudinal monitoring of vector distribution; (2) determining the efficiency of given delivery protocols by measuring target organ/background ratio; and (3) establishing viral or nonviral vector burden for a given organ. These goals are notably different from the purpose of gene expression imaging that potentially allows the endpoint assessment (reviewed in Refs 1 and 2).
and DNA complexes with lipid-based transfection reagents ('lipoplexes') has been performed after systemic or local administration of 99m Tc-PBC-labeled DNA in mice. Imaging results were corroborated with the biodistribution using 99m Tc-PBC and 32 P-labeled DNA and lipoplexes. A markedly different biodistribution of 99m Tc PBC-labeled DNA and lipoplexes was observed with the latter being rapidly trapped in the liver, spleen and lung.
99m Tc PBC-DNA was used as an imaging tracer during in vivo transfection of B16 melanoma by local injection of 'naked' 99m Tc PBC-DNA and corresponding lipoplexes. As demonstrated by nuclear imaging, 99m Tc PBC-DNA lipoplexes showed a slower elimination from the site of injection than 99m Tc PBC-DNA alone. This result correlated with a higher expression of marker mRNA and green fluorescent protein as determined using RT-PCR and immunohistochemistry, respectively. Gene Therapy (2001) 8, 515-522.
Most of our current knowledge about the biodistribution and/or in vivo pharmacokinetics of vector delivery systems still relies on information derived from biopsied or post-mortem tissue samples. The need for longitudinal monitoring of gene delivery justified DNA tagging for magnetic resonance imaging (MRI) applications 3, 4 that can be utilized for studies involving tracking viral, 5 as well as nonviral delivery into cells. 3, 4 Common to these approaches is that the MR imaging reporter is typically attached to the carrier rather than the plasmid DNA itself. Since DNA and carrier are usually bound together as a result of polyelectrolyte complex formation, imaging the carrier does not always reflect the true DNA distribution, particularly if the gene delivery system is labile in vivo.
Nuclear imaging approaches have been previously explored to study the distribution of viral gene delivery vectors in vivo by labeling of enveloped viral particles with 111 In-, 6 or by labeling adenoviral knob proteins with 99m Tc-chelate. 7 Here we report a new family of DNA-binding peptide-based chelates (PBC) designed for covalent labeling of dsDNA with imaging isotopes and demonstrate the utility of these compounds using GlyCys(Acm)-Gly-Cys(Acm)-Gly-Lys 4 -Lys-(N-⑀-[4-(psoralen-8-yloxy)]butyrate)-NH 2 (PBC).
Results
Labeling of PBC with gamma-emitting isotope ( 99m
Tc)
In all experiments double-stranded DNA (dsDNA) was labeled with 99m Tc using a pre-labeled PBC ( Figure 1 ). To optimize PBC labeling with 99m Tc, the efficacy of 99m Tc binding to PBC has been tested by trial labeling in the presence of various amounts of the chelate (0.2-3 nmol, 2.5-30 g PBC) using the reduction of 99m Tc-pertechnetate by stannous(II) cation under alkaline conditions. High pH (Ͼ9) was necessary to de-acetylate C-terminal Smethoxyacetyl cysteines in PBC that are essential for oxotechnetate binding. Chosen reaction conditions resulted in a complete reduction of pertechnetate, whereas the labeling efficiency of PBC exceeded 98% if 0.8-3 nmol of chelate was used (at Ͼ0.5 mCi 99m Tc pertechnetate/labeling reaction, Figure 2a ). Oxotechnetate-labeled PBC eluted as a close doublet peak on C-18 HPLC columns (Figure 2b ). By measuring specific absorption at 320 nm we identified that the first of these peak fractions contained 99% of loaded PBC while the second peak was present only at high PBC concentrations (Ͼ20 m) and may result from oxotechnetate chelation by dimeric (ie partially oxidized) PBC.
Labeling of DNA with 99m TcPBC In a second set of experiments, we determined the efficiency of labeling of plasmid dsDNA (pCMV-GFP 8 ) with 99m TcPBC (Figure 3a ). Approximately 10 pmol dsDNA was mixed with the prelabeled PBC at different stoichiometric ratios (range: 1 mol PBC/2-20 bp DNA, 1/1-10 by charge). Binding of PBC to DNA reached saturation after 10 min incubation at pH 8-9.5. Incubation at relatively low ratios (Ͻ1:10 PBC/base pairs) showed a limited retardation of DNA electrophoretic mobility indicating only partial neutralization of negative charge of DNA by positively charged PBC. Higher amounts of PBC resulted in a partial condensation of DNA (Figure 3a) . The complete condensation of DNA was obtained using a ratio of 1:3 (mol PBC/base pairs). In noncross-linked samples migration of labeled, positively charged PBC to the cathode was clearly visible (Figure 3a , lanes 4 and 5, left panel). According to radioactivity determinations performed using gel-filtration purified DNA, the yield of 99m TcPBC binding to DNA depended on the initial incubation ratio, and ranged from 14 ± 5% (ratio 1:20 mol PBC/bp) to 26 ± 4% (ratio 1:2 mol PBC/bp). The control labeling reaction in the absence of PBC and in the presence of reduced 99m Tc showed that less than 1% of added radioactivity co-purified with dsDNA. Control PBC modified with N-hydroxysuccinimidyl acetate showed low affinity to dsDNA as only 5% of added radioactivity was bound to DNA after the gel-filtration purification step.
UV cross-linking
When PBC/DNA complexes were irradiated using a long-range UV light, PBC binding increased up to 100% indicating that the polyionic complex of PBCs and dsDNA contained approximately 50% weakly interacting PBC molecules that dissociate during the gel filtration. Interaction of these molecules with DNA is apparently stabilized after photo-mediated cycloaddition and crosslinking to pyrimidine residues. 9, 10 The initial ratio of 1:15 mol PBC/bp was used in all further in vivo experiments. This stoichiometric ratio corresponds to the binding of one molecule of PBC per 30 base pairs of DNA in the final irradiated and purified 99m Tc-labeled PBC-DNA. In control experiments involving back-extraction of PBC from complexes with dsDNA we observed binding of PBC by fatty-acid free serum albumin. The addition of excess serum albumin (2 mg/ml final concentration) or plasma (0.1%) to preformed, nonirradiated DNA-PBC complexes resulted in extraction of approximately 50% of DNA-associated radioactivity. After UV irradiation, radioactivity could not be extracted from complexes with albumin treatment.
Further, we demonstrated that dsDNA was crosslinked by PBC by transfecting COS-1 cells with 99m Tc-PBC-labeled expression vector encoding GFP (pCMV-GFP) in vitro using an optimized protocol. 8, 11 The results obtained were compared with control, nonlabeled vector. The results of flow cytometry showed that only 1-3% cells transfected using 99m
Tc-PBC-dsDNA were expressing GFP compared with 63 ± 5% in control cells at 24 h after transfection.
DNA-lipoplexes
The extent of 99m Tc-PBC-dsDNA condensation after irradiation at the ratios Ͻ1:10 (PBC/bp) did not prevent complex formation with positively charged lipids as both 
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GenePorter (GP) and TransIT-100 (T-100) preparations showed almost complete condensation of labeled dsDNA ( Figure 3a , lanes 2 and 3). The complex formation was also observed with partially condensing positively charged graft-copolymer preparation (MPEG-PL, 12 not shown).
In vivo behavior of 99m
Tc-PBC-dsDNA and lipoplexes We further investigated the utility of 99m Tc-PBC for imaging of DNA biodistribution by performing intravenous administration of 99m TcPBC-labeled dsDNA (using pCMV-GFP as a vector) in normal mice. Labeled DNA was administered either as a 'naked' vector or as a complex with a positively charged lipid. The imaging results were then corroborated by a biodistribution study that included 32 P-labeled dsDNA as a labeled tracer. To determine the stability of UV-cross-linked PBC-labeled dsDNA we performed imaging of biodistribution of 99m TcPBC-labeled DNA in animals that received an intravenous injection of either UV-irradiated, or control, non-UV irradiated 99m Tc-PBC labeled dsDNA ( Figure 4a) . A semi-quantitative ROI image analysis of the heart/lung as the region of interest showed that 9-13% of injected dsDNA was present in circulation 5 min after injection, and that 4% of the total dose was still present in the blood pool at 1 h. In animals injected with a control 99m Tc-PBC-dsDNA the activity in the blood pool (heart/lung ROI) was less than 1% at 5 min after injection (Figure 4b ). In animals injected with the control preparation, a fast renal clearance was evident. In both control and experimental animals approximately 50% of the dose were trapped in the liver (Figure 4c ). The biodistribution of the UV-irradiated PBC-dsDNA did not correlate with the biodistribution of the 32 P-labeled vector (Figure 5a ). The urinary excretion of 32 P-labeled vector was more than 10 times greater (9.4 ± 1.3% dose in 1 h) than PBC-labeled (0.82 ± 0.28% dose in 1 h). Additionally, high accumulation of 32 P was observed in bones, heart and muscle. Complexes of labeled dsDNA with positively charged lipids, ie GenePorter or TransIT-100, distributed similarly regardless of whether 32 P or 99m Tc isotopes were used for labeling dsDNA (Figure 5b ). These complexes ('lipoplexes' 13 ) were removed from circulation by liver and spleen at 56% ID/g 1 h after the i.v. injection). Lung accumulated 20-25% ID/g. Intratumoral injection of labeled dsDNA and in vivo transfection. To determine the kinetics of washout of 99m TcPBC-labeled dsDNA or labeled lipoplexes after local injection, animals bearing flank B16 melanoma were used (Figure 6a ). In one group tumors were injected with 35 g of dsDNA vector (pCMV-GFP) mixed at 10:1 (by weight) with 99m TcPBC-labeled pCMV-GFP vector. In other experimental groups tumors were injected with a 99m TcPBC-labeled DNA/nonlabeled vector mixture that was incubated with a positively charged transfection lipids (GP or T-100). Specific radioactivity of tumors was measured as a function of time using a gamma camera and apparent elimination rates were determined. As determined using region-of-interest analysis, the 'naked' 99m TcPBC-DNA (without T-100 or GP) was initially washed out rapidly from the injection site (initial elimination rate 68% injected dose per hour) with a subsequent slower elimination at the rate of 30% ID per hour. The initial washout of both 99m TcPBC-DNA labeled lipoplexes was significantly slower (initial rate 3 and 6% ID per hour for GP and T-100, respectively). During the second slower phase the elimination of lipoplexes formed with GP was slower than of those obtained using T-100 (23 and 39% injected dose per hour, respectively). We detected that approximately 40% ('naked' ds DNA) and 12-19% (lipoplexed ds DNA) were removed from the tumor injection site within 1 h (Figure 6b ).
We further determined the level of GFP gene expression after local administration of the vector in B16 tumors. Under identical injection conditions marker mRNA expression was the highest in the case of GP lipoplexes, as determined 2 or 3 days after the administration (Figure 7a, b) . Relatively low levels of mRNA expression (normalized by ␤-actin mRNA signal) were present in tissues transfected with naked DNA, ie more than 20 times lower than in the case of GP lipoplexes (Figure 7c ). The results obtained using RT-PCR were confirmed by immunohistology that showed prominent staining of tumor cells with the anti-GFP antibodies in tissues injected with lipoplexes, and a very low transfected cell density in the case of the 'naked' expression vector ( Figure 8 ).
Discussion
Nonviral gene therapy is currently perceived as a promising, potentially more safe alternative to the viral counter- part (reviewed in: Refs 14-19). Nonviral methods of gene transfer to mammalian cells are usually less efficient than viral transduction and require substantial optimization. 20 Several serious DNA delivery problems have been identified that include, for example, poor permeability of nuclear membrane for plasmid DNA 21 and complement activation by nonviral transfection complexes. 22 In order to evaluate different gene delivery strategies, it is important to monitor nonviral gene delivery in vitro, as well as in vivo. Monitoring of intracellular transport, distribution and DNA release from complexes can be accomplished with confocal microscopy using terminally labeled oligonucleotide fluorescent probes. [23] [24] [25] [26] The morphology of foreign DNA distribution in cells can also be studied using intact circular DNA labeled with PNAbased triplex-forming clamps 21, 27 or low molecular weight photoreactive fluorescent probes. 28 These approaches have advantages in preserving DNA supercoiling and, in the case of PNA clamps, most of the transcriptional activity of the native expression vector. 21, 27 For in vivo experiments, several techniques have been proposed that involve the use of gamma-emitting isotopes and expression vectors, ie radioiodination for biodistribution 29, 30 or 99m Tc-labeling of linearized DNA and oligonucleotides. 31, 32 Radioiodination has the inherent Gene Therapy disadvantage of inadequate stability and in vivo de-halogenation, while technetium-labeling approaches are not suitable for labeling circular DNA. Since circular, supercoiled dsDNA is the most commonly used in experimental nonviral gene delivery, we set out to design and synthesize heterobifunctional compounds that combine chelating and dsDNA binding properties. We hypothesized that two elements had to be present within a candidate PBC molecule to tightly bind to a DNA duplex: (1) positively charged moieties that initially associate with the DNA phosphodiester backbone; and (2) a major groove binding psoralen that intercalates between adjacent base pairs and covalently binds to a pyrimidine base upon short-term irradiation with near UV range light. 9, 10 The latter ensures irreversibility of binding with resultant stability to dissociation in vivo. After the irradiation, the transcriptionally inactive gamma-emitting 'DNA probe' can serve as a tracer of a fully transcriptionally active expression vector. We developed a two-step dsDNA labeling protocol where the PBC probe is first deprotected in alkaline conditions, labeled in the presence of reduced pertechnetate and then combined with dsDNA. Using optimized protocols we found that Ͼ98% 99m Tc associated with PBC. Mixing of 99m Tc-labeled PBC with dsDNA at low stoichiometric ratios resulted in binding of PBC to the expression vectors and caused minor DNA condensation. This relatively simple labeling procedure combined with UV-cross linking yielded negatively charged 99m TcPBC-DNA with a very high specific radioactivity (Ͼ2 × 10 7 c.p.m./g DNA). High specific radioactivity of the 99m Tc-labeled PBC enabled nuclear imaging of DNA administration in living animals. Systemic administration experiments showed that biodistributions of cross-linked and noncross-linked 99m Tc PBC-dsDNA complexes were markedly different. Only cross-linked 99m TcPBC-dsDNA was clearly detectable in the blood pool (heart and lung region, Figure 4a, b) . This effect cannot be attributed to the dissociation of 99m TcPBC from DNA and binding to plasma components. In noncross-linked 99m TcPBC-dsDNA preparations, radioactivity was almost exclusively present in the liver and kidneys that is indicative of the rapid dissociation of control, non-crosslinked 99m TcPBC-dsDNA complexes in plasma (Figure 4a, b) , presumably as a result of the instability of the noncovalent complex of PBC with DNA.
Further, we demonstrated that 99m
TcPBC-labeled dsDNA retains the ability to form complexes with positively charged lipids and polymers (Figure 3b) , and that the biodistribution of these complexes (eg lipoplexes) is similar to lipoplexes prepared using a control dG(C)T[ P-labeled deoxyguanosine and deoxycytidine monophosphates, the biodistributions of lipid complexes of both labeled DNA types were remarkably similar. In both cases lipoplexes prepared using labeled DNA showed a much higher overall in vivo retention of lipid-bound DNA. This suggests a certain degree of dsDNA protection from degradation by lipid binding and condensation ( Figure 5) .
Gene delivery by direct injection of the expression vectors directly into the tumor is frequently used in experimental cancer gene therapy for transfecting tumor cells with suicide genes. 33 This approach has also been used for inducing antitumor cytokine-mediated response [34] [35] [36] or apoptosis. 37 ,38 Therefore, we tested feasibility of using 99m TcPBC-labeled DNA as a tracer in tracking kinetics of DNA elimination from the injection site. The goal of these imaging experiments was two-fold: (1) to measure DNA retention and washout kinetics from the injection site in flank tumors; and (2) to test whether prolonged retention at the injection site may correlate with the higher marker gene expression. We observed that 99m TcPBC-labeled 'naked' dsDNA was eliminated from the injection site at a much faster initial rate than lipoplexes, ie 68% injected dose per hour versus 3-6% injected dose per hour ( Figure 6 ). These results suggest that the initial retention at the site of local injection may be indicative of potentially favorable outcomes of in vivo transfections. The reversed-transcription/PCR and histology analyses of tumor samples showed that tumor retention of lipoplexes resulted in markedly higher levels of mRNA and marker protein expression (Figures 7 and  8 ). Though the retention at the injection site alone does not necessarily translate into a better transfection yield, the rapid washout from the target site in our experiments clearly correlated with the poor transfection yields. Therefore, our experiments suggest that imaging of local gene delivery is useful for gene delivery monitoring for the purpose of comparing different transfection compositions in vivo.
One of the potential drawbacks of psoralen-based DNA labels is that labeled, cross-linked DNA is transcriptionally inactive and partially condensed. However, this DNA comprises only a fraction of administered expression vector that is fully active. The loss of transcriptional activity of the tracer vector and dsDNA condensation may be potentially avoided in the future, eg by designing triplex forming PNA-based chelating 'clamps'. 21 The inherent advantage of this approach is that PNA clamp binding is sequence-specific and that this allows labeling of dsDNA outside expression cassette. However, only vectors with PNA-complimentary sequences could be labeled using this strategy.
In conclusion, the novel dsDNA-binding peptide analog (PBC) showed efficient labeling of double-stranded DNA with gamma-emitting 99m Tc isotope and allows imaging of vector distribution in intact animals in vivo. This technique facilitates further in vivo studies in which biodistribution of expression vector and gene expression can be studied independently, correlated and consecutively assessed in a noninvasive manner. Noninvasive monitoring of vector delivery will play a major role in developing more efficient nonviral gene therapies. Tc pertechnetate (approximately 3 mCi), followed by 6 l of the deprotection mixture (50 mg/ml sodium tartrate in 0.1 m NH 4 OH/ NH 4 CH 3 COO, pH 9.5). Three l solution of 0.4 mg SnCl 2 .2H 2 0/ml in 0.05 N HCl was then added and the mixture incubated for another 10 min. The radiochemical purity of PBC was analyzed by paper chromatography in acetone (to monitor the presence of pertechnetate). Analysis of stability and concentration dependence was performed on a C-18 column by HPLC (Vydac 1 ml precolumn, gradient: 0-80% acetonitrile in 0.1%TFA).
Materials and methods

Synthesis of PBC
Interaction of DNA with PBC Plasmid DNA (pCDNA3 vector 8 ) was isolated using a Qiagen Megaprep kit. The DNA was added to either 99m Tc-or nonlabeled PBC at different molar DNA:PBC ratios ranging from 1:1500 to 1:100) and incubated for 10 min at RT in a total volume 50-70 l. To bind PBC to DNA irreversibly, the mixture was cooled on ice placed on top of a quartz cuvette filled with 40% cobaltous (II) nitrate solution 10 and irradiated at maximum output for 10 min using a UV transilluminator (Fisher Scientific, Pittsburgh, PA, USA). Labeled plasmid DNA was purified using BioSpin P30 columns (BioRad, Hercules, CA, USA) and routinely analyzed in 0.65% agarose gels by electrophoresis in 10 mm Tris-acetate-EDTA, pH 6. Agarose gels were exposed to Phosphor storage plates (Molecular Dynamics, Sunnyvale, CA, USA) for 20 min, and scanned using a PhosphoImager SI (Molecular Dynamics). Radioactive bands were excised and analyzed for radioactivity in a gamma-counter.
Labeling of DNA with . Each labeling step was followed by a chase step using the corresponding nonlabeled deoxynucleotide (at a final concentration of 0.1 mm. Incubation was for another 15 min at RT in the presence of 1 U Klenow. The plasmid was purified by gel-filtration (BioSpin30), phenol/chloroform-extracted, ethanol-precipitated and the pellet washed once with ethanol. Incorporation of 32 P was verified by scintillation counting. Purified plasmid (1 g) was ligated using 3 Weiss units T4 DNA ligase (plasmid, 3 in 100 l, for 16 h at 15°C). Ligation and regeneration of the restriction site was analyzed by NotI restriction followed by gel electrophoresis.
Lipoplex formation 99m
TcPBC-or 32 P-labeled plasmid DNA was mixed at a ratio of 1:10 with unlabeled DNA. Transfection complexes were prepared using either TransIT-100 (T-100; PanVera, Madison, WI, USA) or GenePorter (GP; Gene Therapy Systems, San Diego, CA, USA) according to the protocols provided by the manufacturers. Complexes were analyzed by electrophoresis and laser light correlation photometry (Coulter MD4; Beckman-Coulter, Hialeah, FL, USA) at 90°scattering and used for in vivo experiments within 10 min.
Animal experiments
Tumor model: Mouse amelanotic melanoma B16 was propagated in DMEM, 10% FCS at 37°C in a humidified 5% CO 2 incubator. Approximately 5 × 10 6 cells were injected in a volume of 50 l into each flank of female C57BL/6 or Swiss nu/nu mice. Tumors were allowed to grow for 10-15 days until they reached 0.5-0.8 cm in diameter.
DNA injection and imaging: Mice (n = 3 per group) were anesthetized using intraperitoneal injection of a ketamine/xylazine mixture. The imaging formulation contained 30 g of either naked or lipid-complexed plasmid DNA, that was labeled with either 150-200 Ci 99m Tc or 2-3 Ci
32
P in a total volume of 175 l Gene Therapy (GP) or 200 l (T-100). The mixtures were slowly injected into the tumors (50 l per min) using a 28-gauge needle.
Imaging was performed immediately after the injection (4 min image acquisition) and repeated in 15-min intervals for 1 h using a gamma camera (Ohio Nuclear, Solon, OH, USA) that had been calibrated using 99m
Tc standards (10-100 Ci/ml). Image analysis was performed using the region-of-interest (ROI) approach and NuclearMac software (Scientific Systems, Boulder, CO, USA).
Analysis of GFP expression: Total RNA was extracted using TRIzol according to the protocol provided by the manufacturer (Gibco BRL, Gaithersburg, MD, USA). Briefly, tumor tissue was homogenized using a Mini Bead-Beater (BioSpec Products, Bartlesville, OK, USA), RNA extracted and first-strand cDNA synthesized using 1 g of total RNA 0.5 g oligo(dT) 15 , 0.5 mm dNTPs (Pharmacia Biotech, Piscatway, NJ, USA), and 100 U Superscript II RNAse H − reverse transcriptase (Gibco BRL) for 90 min at 42°C. The reaction was terminated by heating at 95°C for 10 min. PCR amplification for GFP was carried out in the presence of 10 mm MgCl 2 , 0.2 mm dNTPs, 0.4 m each of forward and forward and reverse primers 39 and 2 U Taq DNA polymerase (Gibco BRL). Following amplification, aliquots of the PCR products were loaded on to 2% (w/v) agarose gels, resolved by electrophoresis, and photographed. Immunohistochemical detection of GFP expression in tumors was performed using an anti-GFP antibody (1:20 dilution; Clontech, Palo Alto, CA, USA) and anti-rabbit-alkaline phosphatase (1:600 dilution; PharMingen, San Diego, CA, USA).
